Puma Biotechnology, Inc.
PBYI
NASDAQ·Healthcare·Biotechnology·Mkt cap $486.1M
$9.55
▲ +1.49%
P/E
18.50
Mkt Cap
$486.1M
52-Wk Range
$4.30–$9.74
52-Week Range
$4.30 - $9.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 109.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary neratinib technology with multiple approved and pipeline indications
- Strategic partnerships with Pfizer and global specialty pharmaceutical companies
- Focused pipeline addressing large HER2-positive and HER2-mutation patient populations
- International distribution network through sub-licensing agreements across key markets
Bear Case
2 risks
- Average volatility.
- Premium valuation to Biotech & Therapeutics peers
Growth
Stable outlook
Expanding neratinib adoption in early-stage and metastatic breast cancer markets
Value
Premium valuation to Biotech & Therapeutics peers
Momentum
Hot
+39.4% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying PBYI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of $0.19 vs $0.04 consensus (+375.0% surprise). Revenue of $56.5M vs $53.0M expected (+6.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+375.0%
Revenue trend · last 8Q
—
-18%
+5%
+11%
-32%
+28%
-3%
+8%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$80.5M
$59.1M
$46.0M
$52.4M
$54.5M
$75.5M
$44.8M
$56.5M
Margins · last 8Q
Gross
77.9%
Operating
13.4%
Profit
14.5%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How PBYI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related